Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6,030 ILa | +2.73% | +15.81% | +58.06% |
May. 13 | Piper Sandler Adjusts Price Target on Teva Pharmaceutical Industries to $20 From $19, Maintains Overweight Rating | MT |
May. 08 | Sector Update: Health Care Stocks Slipping Wednesday Afternoon | MT |
Evolution of the average Target Price on Teva Pharmaceutical Industries Limited
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Teva Pharmaceutical Industries Limited
Piper Sandler | |
JPMorgan Chase | |
Goldman Sachs | |
Barclays | |
Jefferies & Co. | |
BofA Securities | |
HSBC | |
UBS | |
Evercore ISI | |
Bernstein | |
Argus | |
Raymond James |
EPS Revisions
- Stock Market
- Equities
- TEVA Stock
- TEVA Stock
- Consensus Teva Pharmaceutical Industries Limited